Eton Pharmaceuticals director sells 80,555 shares

Each of the five sale entries reports a weighted-average price and a separate range across the trades.

Available on EDGAR 11/10/2026 - 06:21 PM EST Accepted by SEC EDGAR 11/10/2026 - 06:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. director Charles J. Casamento exercised stock options for 80,555 common shares on November 10, 2026, at exercise prices of $7.31, $3.58, $8.61 and $3.78 per share. He also sold 80,555 shares that day in five transactions; the reported weighted-average sale prices were $64.3287, $65.3249, $66.2615, $67.1103 and $67.8695 per share. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 80,555 shares ($4.91M approx. pre-tax spread)

Exercise and Sale 13 txns

Insider CASAMENTO CHARLES J

Role Director

Sold 80,555 shs ($5.35M)

Approx. gross sale proceeds $5.35M

Approx. exercise cost $438K

Approx. pre-tax spread $4.91M

Share of Position Sold 100%

Type	Security	Shares	Price	Value
Exercise	Stock Option F1	12,500	$0.00	$0.00
Exercise	Stock Option F2	27,400	$0.00	$0.00
Exercise	Stock Option F3	19,655	$0.00	$0.00
Exercise	Stock Option F4	21,000	$0.00	$0.00
Exercise	Common Stock	12,500	$7.31	$91K
Exercise	Common Stock	27,400	$3.58	$98K
Exercise	Common Stock	19,655	$8.61	$169K
Exercise	Common Stock	21,000	$3.78	$79K
Sale	Common Stock F5, F6	6,380	$64.3287	$410K
Sale	Common Stock F5, F7	14,715	$65.3249	$961K
Sale	Common Stock F5, F8	22,601	$66.2615	$1.50M
Sale	Common Stock F5, F9	33,956	$67.1103	$2.28M
Sale	Common Stock F5, F10	2,903	$67.8695	$197K

Holdings After Transaction: Stock Option — 29,000 options (Direct); Common Stock — 0 shares (Direct)

Holdings Before and After: Stock Option, 109,555 to 29,000 options (Direct); Common Stock, 0 to 0 shares (Direct)

Footnotes (10)

1. F1. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020.
2. F2. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021.
3. F3. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.
4. F4. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023.
5. F5. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
6. F6. The shares were sold in multiple trades at prices ranging from $63.755 to $64.685. The price reported above reflects the weighted average sales price.
7. F7. The shares were sold in multiple trades at prices ranging from $64.76 to $65.74. The price reported above reflects the weighted average sales price.
8. F8. The shares were sold in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sales price.
9. F9. The shares were sold in multiple trades at prices ranging from $66.76 to $67.61. The price reported above reflects the weighted average sales price.
10. F10. The shares were sold in multiple trades at prices ranging from $67.76 to $67.975. The price reported above reflects the weighted average sales price.

Key Figures

Options exercised and shares acquired: 12,500 shares at $7.31 per share Options exercised and shares acquired: 27,400 shares at $3.58 per share Options exercised and shares acquired: 19,655 shares at $8.61 per share +3 more

6 metrics

Options exercised and shares acquired 12,500 shares at $7.31 per share November 10, 2026

Options exercised and shares acquired 27,400 shares at $3.58 per share November 10, 2026

Options exercised and shares acquired 19,655 shares at $8.61 per share November 10, 2026

Options exercised and shares acquired 21,000 shares at $3.78 per share November 10, 2026

Common shares sold 80,555 shares Five transactions on November 10, 2026

Reported weighted-average sale prices $64.3287, $65.3249, $66.2615, $67.1103 and $67.8695 per share Five transactions on November 10, 2026

Key Terms

weighted average sales price, vested, exercisable

3 terms

weighted average sales price financial

"reflects the weighted average sales price"

vested technical

"vested on a quarterly basis over 12 months"

exercisable technical

"fully vested and exercisable on February 20, 2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What price ranges were reported for Charles J. Casamento's ETON share sales?

On November 10, 2026, the reported ranges were: 6,380 shares, $63.755–$64.685; 14,715 shares, $64.76–$65.74; 22,601 shares, $65.76–$66.75; 33,956 shares, $66.76–$67.61; and 2,903 shares, $67.76–$67.975. The per-transaction prices reported above those ranges are weighted averages.

When did Charles J. Casamento's ETON options become fully vested and exercisable?

The options for 12,500 shares became fully vested and exercisable on February 20, 2020; 27,400 shares on March 12, 2021; 19,655 shares on May 3, 2022; and 21,000 shares on February 7, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASAMENTO CHARLES J

(Last) (First) (Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK ILLINOIS 60010-7208

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2026		M		12,500	A	$7.31	12,500	D
Common Stock	11/10/2026		M		27,400	A	$3.58	39,900	D
Common Stock	11/10/2026		M		19,655	A	$8.61	59,555	D
Common Stock	11/10/2026		M		21,000	A	$3.78	80,555	D
Common Stock	11/10/2026		S		6,380	D	$64.3287(5)(6)	74,175	D
Common Stock	11/10/2026		S		14,715	D	$65.3249(5)(7)	59,460	D
Common Stock	11/10/2026		S		22,601	D	$66.2615(5)(8)	36,859	D
Common Stock	11/10/2026		S		33,956	D	$67.1103(5)(9)	2,903	D
Common Stock	11/10/2026		S		2,903	D	$67.8695(5)(10)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.31	11/10/2026		M			12,500	02/20/2019(1)	02/19/2029	Common Stock	12,500	$0	0	D
Stock Option	$3.58	11/10/2026		M			27,400	03/12/2020(2)	03/11/2030	Common Stock	27,400	$0	0	D
Stock Option	$8.61	11/10/2026		M			19,655	05/03/2021(3)	05/02/2031	Common Stock	19,655	$0	0	D
Stock Option	$3.78	11/10/2026		M			21,000	02/07/2022(4)	02/06/2032	Common Stock	21,000	$0	29,000	D

Explanation of Responses:

1. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020.

2. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021.

3. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.

4. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023.

5. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

6. The shares were sold in multiple trades at prices ranging from $63.755 to $64.685. The price reported above reflects the weighted average sales price.

7. The shares were sold in multiple trades at prices ranging from $64.76 to $65.74. The price reported above reflects the weighted average sales price.

8. The shares were sold in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sales price.

9. The shares were sold in multiple trades at prices ranging from $66.76 to $67.61. The price reported above reflects the weighted average sales price.

10. The shares were sold in multiple trades at prices ranging from $67.76 to $67.975. The price reported above reflects the weighted average sales price.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ Judith Matthews	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)